April 23, 2024Open Access

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Key Points

Key points are not available for this paper at this time.

Abstract

Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase I inhibitor payload via a plasma-stable, selectively cleavable linker.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Bardia et al. (Tue,) studied this question.

www.synapsesocial.com/papers/68e6de6eb6db64358765a50e — DOI: https://doi.org/10.1200/jco.23.01909

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Authors

Aditya Bardia

Ian E. Krop

Takahiro Kogawa

Journals

Journal of Clinical Oncology

Actions

Institutions

Harvard University

University of California, Los Angeles

Massachusetts General Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion